Andrew T Lenis1, Vishnukamal Golla1, Patrick M Lec1, David C Johnson1, Izak Faiena1, Carol Lee2, Siamak Rahman2, Karim Chamie3,4. 1. Department of Urology, David Geffen School of Medicine At UCLA, 300 Stein Plaza, Suite 348, Los Angeles, CA, 90095, USA. 2. Department of Anesthesiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 3. Department of Urology, David Geffen School of Medicine At UCLA, 300 Stein Plaza, Suite 348, Los Angeles, CA, 90095, USA. kchamie@mednet.ucla.edu. 4. Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, USA. kchamie@mednet.ucla.edu.
Abstract
PURPOSE: To assess the impact of N-methylnaltrexone, a peripherally acting mu-opioid receptor antagonist, on the post-operative recovery of patients undergoing robotic-assisted radical cystectomy for bladder cancer. METHODS: We retrospectively reviewed patients undergoing robotic-assisted radical cystectomy by a single surgeon (KC) prior to (control group) and after (treatment group) the routine use of N-methylnaltrexone. Kaplan-Meier curves and the log-rank test were used to quantify time to flatus, bowel movement, and discharge. Daily mean opioid use, daily pain assessment rating, and episodes of severe pain (7-10/10) were compared. Gastrointestinal-related complications, including ileus, emesis, and/or need for post-op nasogastric tube placement, and 30-day readmissions were also compared between groups. Charge capture data were compared between groups to analyze cost impact. RESULTS: 29 patients each in the control and treatment group met inclusion criteria. Patients receiving N-methylnaltrexone had reduced length of stay compared with no N-methylnaltrexone (median 4 vs. 7 days, p < 0.01). Time to flatus and bowel movement, however, were similar. In a multivariable analysis controlling for possible confounders, however, the improvement in length of stay associated with N-methylnaltrexone use did not reach statistical significance (p = 0.11). Episodes of severe pain and composite gastrointestinal-related complications were reduced in the N-methylnaltrexone group (44.8% vs. 10.3%, p < 0.01). The reduction in length of stay was associated with approximately $10,500 in cost savings per patient. CONCLUSIONS: In this study, N-methylnaltrexone was associated with reduced length of stay, fewer episodes of severe pain, and reduced costs. These results provide the impetus for further study.
PURPOSE: To assess the impact of N-methylnaltrexone, a peripherally acting mu-opioid receptor antagonist, on the post-operative recovery of patients undergoing robotic-assisted radical cystectomy for bladder cancer. METHODS: We retrospectively reviewed patients undergoing robotic-assisted radical cystectomy by a single surgeon (KC) prior to (control group) and after (treatment group) the routine use of N-methylnaltrexone. Kaplan-Meier curves and the log-rank test were used to quantify time to flatus, bowel movement, and discharge. Daily mean opioid use, daily pain assessment rating, and episodes of severe pain (7-10/10) were compared. Gastrointestinal-related complications, including ileus, emesis, and/or need for post-op nasogastric tube placement, and 30-day readmissions were also compared between groups. Charge capture data were compared between groups to analyze cost impact. RESULTS: 29 patients each in the control and treatment group met inclusion criteria. Patients receiving N-methylnaltrexone had reduced length of stay compared with no N-methylnaltrexone (median 4 vs. 7 days, p < 0.01). Time to flatus and bowel movement, however, were similar. In a multivariable analysis controlling for possible confounders, however, the improvement in length of stay associated with N-methylnaltrexone use did not reach statistical significance (p = 0.11). Episodes of severe pain and composite gastrointestinal-related complications were reduced in the N-methylnaltrexone group (44.8% vs. 10.3%, p < 0.01). The reduction in length of stay was associated with approximately $10,500 in cost savings per patient. CONCLUSIONS: In this study, N-methylnaltrexone was associated with reduced length of stay, fewer episodes of severe pain, and reduced costs. These results provide the impetus for further study.
Authors: Cheryl T Lee; Sam S Chang; Ashish M Kamat; Gilad Amiel; Timothy L Beard; Amr Fergany; R Jeffrey Karnes; Andrea Kurz; Venu Menon; Wade J Sexton; Joel W Slaton; Robert S Svatek; Shandra S Wilson; Lee Techner; Richard Bihrle; Gary D Steinberg; Michael Koch Journal: Eur Urol Date: 2014-02-26 Impact factor: 20.096
Authors: Francesco Soria; Marco Moschini; David D'andrea; Mohammad Abufaraj; Beat Foerster; Romain Mathiéu; Killian M Gust; Paolo Gontero; Giuseppe Simone; Anoop Meraney; Suprita Krishna; Badrinath Konety; Morgan Rouprêt; Matthew Perry; Edward Rowe; Guillaume Ploussard; Stephen A Boorjian; Peter Wiklund; Prasanna Sooriakumaran; Shahrokh F Shariat Journal: Eur Urol Focus Date: 2018-11-16
Authors: Connor M Forbes; Ali Cyrus Chehroudi; Miles Mannas; Andrea Bisaillon; Tracey Hong; Alan I So; Kelly Mayson; Peter C Black Journal: Can Urol Assoc J Date: 2021-02 Impact factor: 1.862
Authors: Karim Chamie; Vishnukamal Golla; Andrew T Lenis; Patrick M Lec; Siamak Rahman; Eugene R Viscusi Journal: J Gastrointest Surg Date: 2020-08-10 Impact factor: 3.452